First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China.
Qing ChangYanwei ZhangJianlin XuRunbo ZhongHuiping QiangBo ZhangBaohui HanJialin QianTianqing ChuPublished in: Thoracic cancer (2019)
Our study shows that for advanced NS-NSCLC patients with wild-type driver genes, first-line PemPBev might be a better treatment option compared to PacCBev.